Literature DB >> 9667675

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

K Matsui1, N Masuda, M Fukuoka, T Yana, T Hirashima, T Komiya, M Kobayashi, M Kawahara, S Atagi, M Ogawara, S Negoro, S Kudoh, K Furuse.   

Abstract

A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9667675      PMCID： PMC2150367          DOI： 10.1038/bjc.1998.325

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  27 in total

1.  Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

Authors:  J F Bishop; D Raghavan; R Stuart-Harris; G Morstyn; R Aroney; R Kefford; K Yuen; J Lee; P Gianoutsos; I N Olver
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

Authors:  R L Souhami; S G Spiro; R M Rudd; M C Ruiz de Elvira; L E James; N H Gower; A Lamont; P G Harper
Journal:  J Natl Cancer Inst       Date:  1997-04-16       Impact factor: 13.506

3.  Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.

Authors:  P Dombernowsky; N I Nissen
Journal:  Acta Pathol Microbiol Scand A       Date:  1973-09

4.  Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.

Authors:  I E Smith; B D Evans; M E Gore; M D Vincent; L Repetto; J R Yarnold; H T Ford
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

5.  Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer.

Authors:  I E Smith; S J Harland; B A Robinson; B D Evans; L C Goodhart; A H Calvert; J Yarnold; J P Glees; J Baker; H T Ford
Journal:  Cancer Treat Rep       Date:  1985-01

6.  Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

Authors:  M J Egorin; D A Van Echo; S J Tipping; E A Olman; M Y Whitacre; B W Thompson; J Aisner
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

7.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

Authors:  M J Egorin; D A Van Echo; E A Olman; M Y Whitacre; A Forrest; J Aisner
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

9.  Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.

Authors:  J Aisner; P Alberto; J Bitran; R Comis; J Daniels; H Hansen; H Ikegami; J Smyth
Journal:  Cancer Treat Rep       Date:  1983-01

10.  VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  W K Evans; E Eisenhauer; P Hughes; J A Maroun; J Ayoub; F A Shepherd; R Feld
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640
View more
  5 in total

Review 1.  Lung cancer 7: management of lung cancer in elderly patients.

Authors:  R Booton; M Jones; N Thatcher
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

2.  Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.

Authors:  David J Stewart; Constance Johnson; Adriana Lopez; Bonnie Glisson; Jay M Rhee; B Nebiyou Bekele
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

3.  Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer.

Authors:  Christopher D Corso; Charles E Rutter; Henry S Park; Nataniel H Lester-Coll; Anthony W Kim; Lynn D Wilson; Zain A Husain; Rogerio C Lilenbaum; James B Yu; Roy H Decker
Journal:  J Clin Oncol       Date:  2015-10-19       Impact factor: 44.544

4.  Uptake and tolerance of chemotherapy in elderly patients with small cell lung cancer and impact on survival.

Authors:  Stacey Fisher; Turki M Al-Fayea; Marcy Winget; He Gao; Charles Butts
Journal:  J Cancer Epidemiol       Date:  2012-11-29

5.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.

Authors:  H Okamoto; K Watanabe; H Kunikane; A Yokoyama; S Kudoh; T Asakawa; T Shibata; H Kunitoh; T Tamura; N Saijo
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.